Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...

Investing.com -- Shares in Sanofi (EPA: SASY) (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) fell Friday after the pharmaceutical ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as ...

Sanofi acquired DR-0201 from a private clinical ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

US biotech Regeneron and French drugmaker Sanofi are reviewing next steps for their experimental COPD therapy itepekimab ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...

Sanofi (NASDAQ:SNY), in partnership with Vietnam Vaccine JSC (VNVC), officially launched a state-of-the-art vaccine ...